Home page Home page

Foscan
temoporfin

Package leaflet: Information for the patient


Foscan 1 mg/ml solution for injection

Temoporfin


Read all of this leaflet carefully before you start using this medicine because it contains important information for you.


What Foscan looks like and contents of the pack


Foscan solution for injection is a dark purple solution in an amber glass vial, containing 1 ml, 3 ml or 6 ml of solution.

Each pack contains 1 glass vial and a filter. Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer


biolitec Pharma Ltd. Otto-Schott-Str. 15

07745 Jena Germany

Tel.: +49 3641 5195330

Fax: +49 3641 5195331


This leaflet was last revised in

The following information is intended for medical or healthcare professionals only


Foscan 1 mg/ml solution for injection Temoporfin


  1. PACK CONTENTS


    The active substance is temoporfin. Each ml of solution contains 1 mg of temoporfin. The excipients are ethanol anhydrous and propylene glycol. A filter with Luer lock connections for syringe and cannula is provided.


    Each pack provides 1 vial containing 1 ml, 3 ml or 6 ml solution for injection. Each vial represents a single dose and any unused solution must be discarded.


  2. CALCULATION OF DOSE


    Calculate the required dose of Foscan according to the bodyweight of the patient. The dose is

    0.15 mg/kg bodyweight.


  3. ADMINISTRATION OF FOSCAN (96 hours prior to laser illumination of treatment site)


    Foscan must be administered intravenously via an in-dwelling cannula in a large proximal limb vein, preferably in the antecubital fossa. The patency of the in-dwelling cannula should be tested before injection.


    The dark purple colour of the solution together with the amber vial makes a visual check for particulates impossible. Thus, an in-line filter must be used as a precautionary measure and is provided in the package.


    Draw up the entire contents of the vial containing Foscan into a syringe and expel air (Figure 1).


    imageFigure 1

    Attach the filter to the syringe (Figure 2).


    imageFigure 2


    Press the syringe plunger to fill all dead space within the filter. Continue pressing the plunger to expel excess Foscan until the required volume is left in the syringe, allowing sufficient to cover the dead space in the intravenous cannula (Figure 3).


    imageFigure 3


    Attach the syringe and filter to the cannula. Administer the required dose of Foscan by slow intravenous injection, over not less than 6 minutes (Figure 4).


    imageFigure 4


    Remove the intravenous cannula immediately following the injection. Do NOT flush with aqueous solutions such as sodium chloride 9 mg/ml (0.9 %) solution for injection or water for injections.


    Special care should be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.

    Foscan is photosensitive. Once removed from its packaging it should be administered immediately. Where delay is unavoidable, the solution must be protected from light.


  4. LASER ILLUMINATION OF TREATMENT SITE


    Please refer to the laser user manual, and to the microlens fibre-optic user leaflet.


    96 hours after the administration of Foscan, the treatment site is to be illuminated with light at 652 nm from an approved laser source. Light must be delivered to the entire surface of the tumour using an approved microlens fibre-optic. Wherever possible, the illuminated area must extend beyond the tumour margin by a distance of 0.5 cm.

    Light must be administered not less than 90 hours and not more than 110 hours after Foscan injection. The incident light dose is 20 J/cm2, delivered by the microlens fibre-optic in a circular field to the

    tumour surface at an irradiance of 100 mW/cm2, implying an illumination time of 200 seconds.


    Each field is to be illuminated once only at each treatment. Multiple non-overlapping fields may be illuminated. Care must be taken to ensure that no area of tissue receives more than the specified light dose. Tissue outside the target area must be shielded completely to avoid photoactivation by scattered or reflected light.


  5. SAFETY INFORMATION


Foscan is non-irritant.


Any unused medicinal product or waste material should be disposed of in accordance with local requirements.